Answer questions and earn CME/CNE The concept of frailty has become increasingly
recognized as one of the most important issues in health care and health outcomes and is of …

ABSTRACT Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple
myeloma (MM) treatment; however, their long-term use can be limited by parenteral …

The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab
plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory …

Multiple myeloma (MM) typically affects elderly patients, with a median age at diagnosis of
69 years. 1 Treatment of elderly patients is challenging due to frailty, comorbidities, and …

Multiple myeloma (MM) is primarily a disease of elderly patients. Geriatric aspects in the
context of MM have been poorly investigated until recently. Treatment outcomes for geriatric …

The increasing incidence of geriatric patients with multiple myeloma has elevated concerns
in clinical practice. While the introduction of novel therapeutic agents has substantially …

Multiple myeloma (MM) is the second most common hematological malignancy. Despite the
huge therapeutic progress thanks to the introduction of novel therapies, MM remains an …

Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM).
However, there are few real-world reports of their incidence. In this study, a database of …

Background Progression-free survival (PFS) and overall survival (OS) of newly diagnosed
multiple myeloma (MM) patients have been widely published in the clinical trials setting, but …

Objective We evaluated the efficacy and safety of pomalidomide, bortezomib, and
dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and …